Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
headphones
HealthTree Podcast for Multiple Myeloma

HealthTree Podcast for Multiple Myeloma

HealthTree Podcast for MM

HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
Share icon

All episodes

Best episodes

Seasons

Top 10 HealthTree Podcast for Multiple Myeloma Episodes

Goodpods has curated a list of the 10 best HealthTree Podcast for Multiple Myeloma episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to HealthTree Podcast for Multiple Myeloma for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite HealthTree Podcast for Multiple Myeloma episode by adding your comments to the episode page.

HealthTree Podcast for Multiple Myeloma - mPatient Myeloma Radio: Dr. Guido Tricot, University of Iowa
play

07/12/13 • 52 min

This week on mPatient Myeloma Radio, listen to Dr. Guido Tricot discuss his latest research and open clinical trials.
bookmark
plus icon
share episode
HealthTree Podcast for Multiple Myeloma - Myeloma Crowd Radio: Shaji Kumar, MD, Mayo Clinic on ETBs in Myeloma
play

01/06/22 • 51 min

A new approach in myeloma immunotherapies is in the works called Engineered Toxic Bodies (ETBs). Early on, Molecular Templates partnered with Takeda Oncology to begin development on an ETB therapy for multiple myeloma targeting CD38. Currently, Molecular Templates is moving this therapy forward. ETBs work differently from monoclonal antibodies because they move deep inside the plasma cell instead of flagging the cell's surface. They also don't rely on the body's own immune system (like T cells or NK cells) to kill myeloma. Learn more about this emerging therapy from Dr. Shaji Kumar on this fascinating program. Thanks to our episode sponsor, Takeda Oncology
bookmark
plus icon
share episode
HealthTree Podcast for Multiple Myeloma - Myeloma Crowd Radio: Cristina Gasparetto, MD Duke University & Mark Newman, OD
play

10/04/21 • 73 min

All cancer therapies come with some type of side effect. One newly approved therapy called BLENREP, by GSK, is an antibody drug conjugate targeting BCMA that can cause a condition called keratopathy. Keratopathy is an eye condition that can be mild, so patients don't even know they have it, or it can be more severe. Myeloma specialist Dr. Cristina Gasparetto, MD from Duke University and Mark Newman, OD of OPTIX Eye Center will share in this show how keratopathy can be successfully managed for patients on BLENREP. Learn what keratopathy is, how care is coordinated between the myeloma doctor and the eye doctor, and what patients should know about keratopathy before starting on this therapy. Thanks to our episode sponsor, Takeda Oncology
bookmark
plus icon
share episode
HealthTree Podcast for Multiple Myeloma - Myeloma Crowd Radio: Peter Voorhees, MD, Levine Cancer Institute
play

05/18/21 • 64 min

Myeloma experts are beginning to use antibodies in earlier lines of myeloma treatment, even for newly diagnosed patients. Learn what recent clinical trials are using antibody therapies such as daratumumab and isatuximab in early quad (four) drug combinations for newly diagnosed patients. Peter Voorhees of the Levine Cancer Institute joins Myeloma Crowd Radio to share his experience and findings from these clinical trials. He will discuss the early use and their use as maintenance therapy following stem cell transplant. Is earlier use better? Should they be "saved" for later? When should patients consider using the monoclonal antibodies as maintenance therapy with or without traditional drugs like lenalidomide? Dr. Voorhees will help answer these very practical questions for the myeloma community. Thanks to our episode sponsor, Karyopharm Therapeutics.
bookmark
plus icon
share episode
HealthTree Podcast for Multiple Myeloma - Myeloma Crowd Radio: Sascha Tuchman, MD, University of North Carolina
play

05/14/21 • 62 min

AL Amyloidosis is a secondary condition that can occur in patients with multiple myeloma and can cause protein buildup in organs like the heart, kidneys, liver and nerves. Join Myeloma Crowd Radio by HealthTree to hear from Sascha Tuchman, MD of the University of North Carolina at Chapel Hill as he shares amyloidosis symptoms, treatments and open clinical trials. Thanks to our episode sponsor, Takeda Oncology
bookmark
plus icon
share episode
HealthTree Podcast for Multiple Myeloma - Myeloma Crowd Radio: Noopur Raje, MD, Massachusetts General Hospital
play

04/16/21 • 62 min

CAR T therapy has been in development for over 20 years. The first CAR T therapy is now available for the treatment of multiple myeloma. The ide-cel treatment (now called Abecma) is now FDA approved for multiple myeloma relapsed or refractory patients. In this show, Dr. Noopur Raje of Mass General Hospital will share how the CAR T cell therapy works, outcome data from clinical trials, a review of patients who are eligible to join and when patients should consider the therapy in context of other therapies. Ide-cel (Abecma) is a product developed by Bristol Myers Squibb and blubird bio. Thanks to our episode sponsor, Oncopeptides
bookmark
plus icon
share episode
HealthTree Podcast for Multiple Myeloma - Myeloma Crowd Radio: Robert Z. Orlowski, MD, PhD, MD Anderson Myeloma in 2021
play

01/22/21 • 84 min

Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2021. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2021, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show. Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society’s Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thanks to our episode sponsor, Karyopharm Therapeutics
bookmark
plus icon
share episode
HealthTree Podcast for Multiple Myeloma - Myeloma Crowd Radio: Irene Ghobrial, MD, Dana Farber Cancer Institute Impact
play

12/16/20 • 64 min

Dr. Irene Ghobrial joins Myeloma Crowd Radio to share a study to identify discoveries that could potentially inform COVID-19 treatment decisions and prevention policies in the IMPACT study. Myeloma patients are known to be immunocompromised and may be at higher risk for poor outcomes. IMPACT is a study to identify the prevalence and unique characteristics of COVID-19 in individuals with precursor conditions to hematologic malignancies and in healthy populations. It is enrolling individuals nationwide who are enrolled in the PCROWD and PROMISE studies. All participants enrolled in IMPACT are screened using a blood test for active SARS-CoV-2 and/or antibodies. Participants are then followed and undergo additional blood collection and testing over a one-year period. The overall goal of IMPACT is to understand the short- and long-term impact of COVID-19 on the immune system of healthy individuals and individuals with underlying immune dysregulation. Thanks to our episode sponsor, Bristol Myers Squibb
bookmark
plus icon
share episode
HealthTree Podcast for Multiple Myeloma - Myeloma Crowd Radio: Joshua Richter, MD, Mount Sinai COVID update
play

11/06/20 • 68 min

The coronavirus continues to be a global concern for all citizens and especially for cancer patients. Where are we at now with our learning over the last seven months? Dr. Joshua Richter re-joins Myeloma Crowd Radio for an update on how myeloma patients are and should be navigating during the coronavirus pandemic. Thanks to our episode sponsor, Takeda Oncology
bookmark
plus icon
share episode
HealthTree Podcast for Multiple Myeloma - Myeloma Crowd Radio: Yogesh Jethava, MD, University of Iowa
play

04/18/19 • 83 min

A new clinical trial is open combining low dose melphalan, a drug commonly used at high doses for stem cell transplant, and high dose intravenous Vitamin C. Learn more about how these two treatments work synergistically and why they have been combined in a clinical trial at the University of Iowa. The University of Iowa has unique experience with IV Vitamin C and Dr. Yogesh Jethava joins Myeloma Crowd Radio to share this fascinating open study now enrolling patients. Dr. Yogesh Jethava is Associate Professor and Director of the Multiple Myeloma program as well as Associate Director of the Blood and Marrow Program at the University of Iowa. Prior to this appointment, he was director of the Bone Marrow and Stem Cell Transplant Services Division of Hematology Oncology at the Winthrop P. Rockefeller Cancer Institute at University of Arkansas for Medical Sciences or UAMS where he established the first fully functional allo transplant unit. There, he was Director and Attending Physician for the Leukemia and Lymphoma Subspecialty Clinic. Dr. Jethava is an International Myeloma Working Group member and part of the EMBT malignancy working group and is a member of the Experimental Therapeutics groups and others. He reviews abstracts for publications like blood leukemia in the Blood Cancer Journal, and he is also working on studies that involves high dose vitamin C infusions for plasma cell disorders like myeloma.
bookmark
plus icon
share episode

Show more best episodes

Toggle view more icon

FAQ

How many episodes does HealthTree Podcast for Multiple Myeloma have?

HealthTree Podcast for Multiple Myeloma currently has 223 episodes available.

What topics does HealthTree Podcast for Multiple Myeloma cover?

The podcast is about Health & Fitness and Podcasts.

What is the most popular episode on HealthTree Podcast for Multiple Myeloma?

The episode title 'Myeloma Crowd Radio: Shaji Kumar, MD, Mayo Clinic on ETBs in Myeloma' is the most popular.

What is the average episode length on HealthTree Podcast for Multiple Myeloma?

The average episode length on HealthTree Podcast for Multiple Myeloma is 66 minutes.

How often are episodes of HealthTree Podcast for Multiple Myeloma released?

Episodes of HealthTree Podcast for Multiple Myeloma are typically released every 11 days, 4 hours.

When was the first episode of HealthTree Podcast for Multiple Myeloma?

The first episode of HealthTree Podcast for Multiple Myeloma was released on Jul 5, 2013.

Show more FAQ

Toggle view more icon

Comments